Targeting TNF-α for the treatment of inflammatory bowel disease

Billiet, Thomas; Rutgeerts, Paul; Ferrante, Marc; Assche, Gert Van; Vermeire, Séverine

doi:10.1517/14712598.2014.858695

Cited by 117 publications

(85 citation statements)

References 157 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is a particularly difficult question to answer because the efficacy of drugs has such high variability and may change in an individual over time. Although surgery rates have decreased (17)(18)(19) and the need for surgery can be delayed in individuals by improved therapy with biologicals (20), the course of the disease over the years remains highly unpredictable. The evolving concept of tailored, 'personalized' management of IBD and treating the disease to an objective target are high in the priority of information needs of patients, and clinicians are beginning to realize that the personalized treatment approach can lead to higher remission rates and shorter initial disease duration (21).…”

Section: Data Presented As N (%)mentioning

confidence: 99%

Living with Inflammatory Bowel Disease: A Crohn’s and Colitis Canada Survey

Becker

Grigat

Ghosh

et al. 2015

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

BACKGROUND: Despite improvements in therapies for inflammatory bowel diseases (IBDs), patient quality of life continues to be significantly impacted.OBJECTIVE: To assess the impact of IBD on patients and families with regard to leisure, relationships, mental well-being and financial security, and to evaluate the quality and availability of IBD information.METHODS: An online survey was advertised on the Crohn’s and Colitis Canada website, and at gastroenterology clinics at the University of Alberta Hospital (Edmonton, Alberta) and University of Calgary Hospital (Calgary, Alberta).RESULTS: The survey was completed by 281 IBD patients and 32 family members. Among respondents with IBD, 64% reported a significant or major impact on leisure activities, 52% a significant or major impact on interpersonal relationships, 40% a significant or major impact on financial security, and 28% a significant or major impact on planning to start a family. Patient information needs emphasized understanding disease progression (84%) and extraintestinal symptoms (82%). There was a strong interest in support systems such as health care insurance (70%) and alternative therapies (66%). The most common source of information for patients was their gastroenterologist (70%); however, most (70%) patients preferred to obtain their information from the Crohn’s and Colitis Canada website.CONCLUSIONS: The impact of IBD on interpersonal relationships and leisure activities was significant among IBD patients and their families. Understanding the disease, but also alternative treatment options, was of high interest. Currently, there is a discrepancy between interest in information topics and their availability. Respondents reported a strong desire to obtain information regarding disease progression, especially extraintestinal symptoms.

show abstract

Section: Data Presented As N (%)mentioning

confidence: 99%

Living with Inflammatory Bowel Disease: A Crohn’s and Colitis Canada Survey

Becker

Grigat

Ghosh

et al. 2015

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

show abstract

“…1 These drugs are however associated with high manufacturing costs and together with the long duration of treatment, this represents true challenges for the current health care budget. 2 Furthermore, the possibility of infectious or oncologic adverse events further feed the debate if therapy can be stopped once remission is achieved and if so, when, how and in whom.…”

Section: Introductionmentioning

confidence: 99%

Long-Term Outcome of Patients With Crohn’s Disease Who Discontinued Infliximab Therapy Upon Clinical Remission

Papamichael

Casteele

Gils

et al. 2015

Clinical Gastroenterology and Hepatology

Self Cite

View full text Add to dashboard Cite

“…Additionally, a few studies used IFX or ADA in active fistulizing CD in adult patients 47) 48) . However, although 60 to 80 percent of patients showed a good initial response to anti-TNF therapy for CD and UC, only one third of patients remained in clinical remission without steroids at one year 45) . Currently, IFX (Remicade; Mitsubishi Tanabe Pharma Corp, Tokyo, Japan) is a chimeric immunoglobulin G (IgG) human (75%)/murine (25%) mAb administered by intravenous infusion, is indicated for induction and maintenance of remission in adult and paediatric CD and for induction and maintenance of remission in patients with UC 49) .…”

Section: )-45)mentioning

confidence: 97%

Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives

Osada

Watanabe

2015

Juntendo Medical Journal

View full text Add to dashboard Cite

In recent years, landmark progress has been made in the treatment of patients with inflammatory bowel diseases (IBD). The anti-tumour necrosis factor (TNF)-α antibody era has shown that mucosal healing is a key therapeutic goal, and may predict the sustainability of remission or resection-free survival in IBD patients.Further, the anti-TNF-α antibody infliximab (IFX) became an alternative medication for refractory UC in 2010 under the Japan national health reimbursement scheme. However, to induce remission in steroid-refractory UC, currently several therapeutic options are available in Japan including cytapheresis, tacrolimus, and anti-TNF-α biologics, but as yet, there are no guidelines for the sequence and timing of these therapeutic interventions.Additionally, there are many patients who do not respond, or are intolerant, to anti-TNF-α biologics. Recently, new strategies like faecal microbiota transplantation and anti-leucocyte infiltration have been tested for induction and maintenance of remission in IBD patients. This paper provides an overview of the latest treatment options and future perspectives in IBD therapy.

show abstract

Targeting TNF-α for the treatment of inflammatory bowel disease

Cited by 117 publications

References 157 publications

Living with Inflammatory Bowel Disease: A Crohn’s and Colitis Canada Survey

Living with Inflammatory Bowel Disease: A Crohn’s and Colitis Canada Survey

Long-Term Outcome of Patients With Crohn’s Disease Who Discontinued Infliximab Therapy Upon Clinical Remission

Current Treatment Options for Inflammatory Bowel Diseases and Future Perspectives

Contact Info

Product

Resources

About